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Preclinical xenograftmodelshavecontributed toadvancingourunderstandingof themolecular basisofprostatecancer and
to the development of targeted therapy. However, traditional preclinical in vivo techniques using calipermeasurements and
survival analysis evaluate the macroscopic tumor behavior, whereas tissue sampling disrupts the microenvironment and
cannot be used for longitudinal studies in the same animal. Herein, we present an in vivo study of [18F]-fluorodeoxyglucose
(FDG) positron emission tomography (PET)/computed tomography (CT) designed to evaluate the metabolism within the
microenvironment of LAPC4-CR, a unique murine model of castration-resistant prostate cancer. Mice bearing LAPC4-CR
subcutaneous tumorswere administered [18F]-FDGvia intravenous injection. After a 60-minute distribution phase, themice
were imaged on a PET/CT scanner with submillimeter resolution; and the fused PET/CT images were analyzed to evaluate
tumor size, location, andmetabolism across the cohort of mice. The xenograft tumors showed [18F]-FDG uptake that was
independent of tumor size and was significantly greater than uptake in skeletal muscle and liver in mice (Wilcoxon signed-
rank P values of .0002 and .0002, respectively). [18F]-FDGmetabolism of the LAPC4-CR tumors was 2.1 ± 0.8 ID/cm3*wt,
with tumor to muscle ratio of 7.4 ± 4.7 and tumor to liver background ratio of 6.7 ± 2.3. Noninvasive molecular imaging
techniques such as PET/CT can be used to probe the microenvironment of tumors in vivo. This study showed that [18F]-
FDG-PET/CT could be used to image and assess glucose metabolism of LAPC4-CR xenografts in vivo. Further work can
investigate the use of PET/CT to quantify themetabolic response of LAPC4-CR to novel agents and combination therapies
using soft tissue and possibly bone compartment xenograft models.
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Prostate cancer is the second leading cause of cancer death in
American men [1]. Nearly all prostate cancer deaths are due to
metastatic disease that has emerged once the disease becomes resistant
to castration and is referred to as castration-resistant prostate cancer
(CRPC). The drivers of prostate cancer cell proliferation, metastasis,
and evasion of apoptosis include activation of the androgen receptor,
carcinogenic signaling within cells, and the effect of survival signals
from the microenvironment. Regression or stabilization of cancer
burden occurs in some CRPC patients through the use of hormonal
therapy [2,3], cytotoxic therapy [4,5], and immune-based therapy [6]
that abrogates one or more of these drivers. An alpha-emitting
radiopharmaceutical [7] is also currently used clinically in CRPC
patients with skeletal metastases to prolong overall survival and
localized radiation cell killing in bone metastases. Metastatic CRPC
will typically progress despite therapy as a result of redundant or
adaptive resistance mechanisms. Improvements in patient outcomes
will require preventing resistance through multitargeted approaches
against the key drivers of prostate cancer. As such, there is a need for
informative in vivo studies of CRPC.
Preclinical xenograft models of CRPC have contributed toward
advancing the understanding of the molecular basis of the disease, as
well as developing and testing innovative therapies. However,
traditional preclinical investigative methods of tumor volume measure-
ments and survival studies provide no information about the molecular
basis of tumor response to therapy or development of resistance,
whereas tissue sampling and histochemical assays have limited use for
longitudinal studies. Noninvasive in vivomolecular imaging techniques
such as positron emission tomography (PET)/computed tomography
(CT) can be used to probe the microenvironment in preclinical models
of cancer and in clinical cancer patients.
[18F]-fluorodeoxyglucose (FDG) is taken up by tumor cells according
to the glycolytic rate (Warburg effect). Therefore, [18F]-FDG-PET/CT
may be used to assess the extent of malignancy and detect disease in both
soft tissue and osseous compartments, and could serve as a biomarker for
assessment of treatment response and outcome measures in CRPC.
[18F]-FDG-PET was able to assess treatment effects that would usually
only be appreciated by a combination of prostate-specific antigen,
[99mTc]-methylene diphosphonate bone scan, and anatomic imaging in
patients being treated for CRPC [8]. The intensity of [18F]-FDG and
[99mTc]-methylene diphosphonate uptake at osseous sites of disease, on
PET and bone scan, respectively, was found to be prognostic of overall
survival in patients with metastatic prostate cancer [9]. [18F]-FDG
uptake measured at baseline in bone and soft tissue metastases on PET
was also reported to be prognostic of overall survival in patients with
CRPC [10]. Serial [18F]-FDG-PET/CT also allows longitudinal
assessment within a single subject or group of subjects within a cohort,
with highly reproducible measurement [11–14].
This article presents the results of an investigation of [18F]-FDG-PET/
CT as a noninvasive imaging method of LAPC4-CR, the preclinical
model of the aggressive CRPC subtype. In published preclinical studies of
hormone-independent (PC-3, DU145) and -dependent (CWR22,
PAC120) cell lines, [18F]-FDG-PET was found to be an effective in
vivo imaging method for assessing response to androgen deprivation for
PC-3 and CWR22 xenografts [15]. [18F]-FDG-PET has also been
investigated for imaging the androgen-dependent wild-type LAPC4 cell
line in xenograft models [16]. However, to our knowledge, this is the first
publication of in vivo [18F]-FDG-PET/CT imaging of the castrate-
resistant LAPC4-CR xenograft model.Methods and Materials
All experiments were performed in accordance to institutional animal
care and use committee guidelines established at the Dana-Farber
Cancer Institute and conducted within the barrier facility at the Lurie
Family Imaging Center of the Center for Biomedical Imaging in
Oncology (CBIO/LFIC).
In February 2013, 6-week-old female Nu/Nu mice were housed in
cages equipped with filtered ventilation and watering systems, with free
access to food and environmental enrichment, and kept in climate-
controlled negative pressure rooms with 12-hour circadian light/dark
cycles. LAPC4-CR tumor fragments of size of approximately 2 mm3
(approximately 1 million cells) were surgically implanted subcutane-
ously in the right flank of 20mice. Growth of the implanted tumors was
monitored biweekly, and tumor volumes were estimated from caliper
measurements as ½*L*W2. Mice were imaged when tumor volume
reached a size of approximately 100 mm3, which occurred between 5
and 14weeks after the implantation of tumor fragments for 13 of the 20
mice. All 20 implanted mice developed subcutaneous tumors; however,
the tumor size in 7 mice remained too small to meet the imaging
protocol criteria. Mice were humanely sacrificed using institutional
animal care and use committee–approved methods after imaging.
The 13 mice bearing LAPC4-CR subcutaneous tumors larger than
100 mm3 were imaged with [18F]-FDG-PET/CT. The mice were
intravenously administered 331 ± 50 μCi (12.2 ± 1.85 MBq) of
[18F]-FDG via a lateral tail vein injection as an approximately 100-μL
bolus followed by a 100- to 200-μL flush with phosphate-buffered
saline. [18F]-FDG was manufactured by a commercial radiopharma-
ceutical manufacturer (PETNET Solutions Inc) and supplied in
ethanol-stabilized sodium chloride solution. Mice were imaged 61 ± 1
minutes after the injection to produce images with good tumor
contrast by allowing time for accumulation of [18F]-FDG within
metabolically active tissue and clearance from surrounding muscle
and blood pool. This uptake period (time between radiotracer
injection and image acquisition initiation) was kept consistent for all
mice to ensure that the radiotracer distribution was at similar point of
the plateau in [18F]-FDG pharmacokinetics, where tumor uptake was
slowly rising and background tissue uptake was slowly decreasing.
Mouse preparation protocol factors such as anesthesia, external
warming, and restricted diets or fasting affect intersubject variation in
[18F]-FDG metabolism and biodistribution in mice [17]. Therefore,
the mice were placed in clean cages and fed a high-fat, low-protein,
and low-carbohydrate ketogenic diet with free access to water for 12
to 16 hours before the [18F]-FDG-PET/CT. The mice were
anesthetized using an inhaled anesthesia (2%-3% sevoflurane and
air) during the injection of radiotracer and were kept unconscious
during the uptake period and imaging to minimize intersubject
variation in [18F]-FDG metabolism in skeletal muscle and cerebrum.
Warming was used to maintain healthy core body temperature of the
nude mice during periods of unconsciousness and to minimize
brown-fat metabolism from hypothermia. Therefore, the mice were
warmed for 1 hour on circulating warm water heating pads before
bring injected with radiotracer and were kept warm throughout the
unconscious uptake phase and during image acquisition.
All images were acquired using an Inveon Multi-Modality scanner
(Siemens Medical Solutions USA, Inc), a small-animal PET/CT
system that has a lutetium oxyorthosilicate detector PET camera with
36 cps/kBq sensitivity and nominal spatial resolution of 1.6 mm full
width at half maximum [18], and a cone-beam CT camera capable of
high-resolution CT imaging up to 15-μm resolution. For in vivo
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0.2-mm pixel size CT images for anatomic localization and tumor
volume measurement. CT projections were acquired in step and
shoot beams at 1° intervals over a 210° arc, using 80-kVp 0.5-mA
cone-beam x-rays and 0.135 seconds per projection. The PET images
were acquired as 10-minute static acquisitions using detector settings
of 350 to 650 keV energy window, a 3.432-nanosecond coincidence
timing window, and the full 38° axial acceptance angle to increase the
number of acquired positron emission counts and reduce image noise.
CT images were reconstructed using a Feldkamp convolution-back-
projection algorithm, whereas PET images were reconstructed with a
combined iterative algorithm of three-dimensional Ordered Subset
Expectation Maximization and maximum a posteriori estimation for
uniform spatial resolution recovery to 0.8 mm full width at half
maximum. Image fusion and analysis were done on an Inveon
Research Workstation (Siemens Medical Solutions USA, Inc) and
Hermes Hybrid Viewer (HERMES Medical Solutions).
PET image values were normalized by the administered radioac-
tivity of the tracer adjusted for physical decay (injected dose) and the
body weight of the mouse. The body weight of each mouse was
measured and recorded on the day of imaging, and used as an estimate
of the volume of distribution or total volume of tissue into which the
radiotracer was distributed during the uptake period. The normalized
PET value is sometimes referred to as the standardized uptake value, a
semiquantitative measurement of [18F]-FDG metabolism in clinical
imaging, or the ID/cm3*wt in preclinical imaging, and is calculated
according to Eq. (1):
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The [18F]-FDG-PET/CT images were evaluated to determine
anatomic and metabolic tumor volumes and the metabolism in tumor
versus the background metabolism in normal tissue. Fused PET/CT
images were used to locate the tumor, organs, and other tissues. The
CT images were used to delineate the anatomic boundary for the
volumes of interest (VOIs), whereas the PET images were used to
measure the [18F]-FDG metabolism (ID/cm3*wt) in the VOIs. The
anatomic tumor volume was defined from the CT images by drawing
a 3D ellipsoid VOI to just enclose the subcutaneous lesion, as shown
in Figure 1(A). The metabolic tumor volume of the lesion was defined
as the VOI where the [18F]-FDG metabolism was at least 70% of the
maximum value measured within that lesion. The metabolic tumor
volume thus excluded necrotic regions of the tumor, scar tissue,
calcification, and other metabolically inactive tissues, as shown in
Figure 1(B). The [18F]-FDG metabolism was reported as a maximum
(max) and mean (mean70%) ID/cm3*wt within the metabolic tumor
volume. The background [18F]-FDG metabolism in normal muscle
and in normal liver parenchyma was measured by placing a
3-mm-diameter sphere VOI within the flank muscle contralateral
to the xenograft and within the right hepatic lobe 2 to 3 mm inferior
from the diaphragm. The mean within the liver VOI was used to
calculate the tumor to background ratio, TBR [ID/cm3*wt]/liver,
and the mean in skeletal muscle VOI was used to calculate the tumor
to muscle ratio, TMR [ID/cm3*wt]/muscle, of Table 1. During
image analysis, each tumor was segmented into 30 spatial subregions,
and the local maximum [18F]-FDG uptake was measured within each
subregion. The intratumor heterogeneity of metabolism was thencalculated as the range, interquartile range (IQR), and the percentage
differences between the quartiles of local maximum [18F]-FDG
uptake in the subregions, as shown in Table 1.
Results
The mice showed the expected biodistribution of [18F]-FDG in
normal tissues, with radiotracer uptake seen in cardiac muscle,
cerebellum, and harderian glands as well as physiologic excretion via
the kidneys and urinary bladder (Figure 2). There was homogeneous
[18F]-FDG activity in the liver and skeletal muscle. There was
moderate to high [18F]-FDG activity in the LAPC4-CR xenografts
compared with adjacent soft tissue liver and muscle (Figure 3 and
Table 1). The xenograft metabolism was 4 to 11 times higher than
liver, 3 to 19 times higher than muscle (Table 1), and significantly
higher than normal tissue (Wilcoxon signed-rank P value b .01,
Figure 4). The intratumor heterogeneity, IQR of local metabolism in
subregions within the xenografts, was 78 ± 39% (Table 1). The
[18F]-FDG-PET/CT images of 12 tumors showed enhanced
[18F]-FDG activity at the rim and a photopenic center suspicious
of necrosis. The tumor with the smallest CT tumor volume, mouse
ID# 04F01 with 81 mm3, did not show the imaging characteristics of
a necrotic core; however, the [18F]-FDG metabolism in that tumor
fell within the range of the other tumors (Figure 5A and Table 1).
The [18F]-FDG activity in the LAPC4-CR xenograft was not
dependent on tumor size, and there was no correlation of [18F]-FDG
metabolism and anatomic or metabolic tumor volume (Figure 5).
[18F]-FDG metabolism was also not dependent on the number of
days any of the tumors required to grow to greater than 100 mm3 in
size (Figure 5). The anatomic tumor volume measured by CT was
188 ± 62 mm3. The tumor volumes estimated using calipers and the
tumor volumes measured on CT images were similar (Wilcoxon
signed-rank P value = .06), but there was no significant concordance
between the values (Spearman ρ = 0.4, P value = .1). The
metabolically active tumor was smaller than the anatomic tumor
volume (Figure 1B). The metabolic volume of the LAPC4-CR
xenograft was 16.5 ± 11.8 mm3 with [18F]-FDG metabolism (mean
70%) 2.1 ± 0.8 [ID/cm3*wt] (Table 1).Discussion
The data detailed above provide the experimental details used to
enable the evaluation of a new prostate cancer cell line xenograft by
[18F]-FDG-PET/CT. Our preclinical [18F]-FDG-PET/CT protocol
included several animal handling considerations that are necessary to
improve image quality and lesion detectability and to maintain
consistent physiologic [18F]-FDG uptake in mice. High blood
glucose concentrations are associated with hyperinsulinemia and
resulting altered biodistribution with preferential [18F]-FDG uptake
in skeletal muscles [19]. Basal blood glucose level can be reduced in
preclinical and clinical studies through many hours of fasting;
however, a ketogenic diet of high fat, low protein, and low
carbohydrate was used as an alternative to fasting in tumor-bearing
mice. In a conference abstract from researchers at the CBIO/LFIC,
the ketogenic diet resulted in similar low basal blood glucose level
within cohorts of mice, whereas hypoglycemia was observed in some
fasted mice [20]. Because hyperthermia increases the incidence of
metabolically active brown adipose tissue in rodents [17,21,22], the
body temperature of the mice was controlled with external heating.
Likewise, injected ketamine anesthesia is associated with increased
metabolically active brown adipose tissue in rodents and elevated
Figure 1. Orthogonal CT (a) and fused [18F]-FDG-PET/CT (b) views of a subcutaneous LAPC4-CR tumor in a murine xenograft model. The
anatomic tumor volume was estimated by drawing a 3D ellipsoid around the visible tumor boundary on the CT images. The metabolic
tumor volume was estimated by determining the volume of the anatomic tumor that had [18F]-FDG uptake of at least 70% of the
maximum uptake within the tumor (70% threshold).
able 1. Results of the Analysis of Tumor Volume and Tumor Metabolism in LAPC4-CR Xenograft Models Using [18F]-FDG-PET/CT
ouse ID Tumor
Growth
Caliper Volume
Estimate
CT Tumor
Volume
FDG Metabolic
Volume
FDGMetabolism
Max
FDG Metabolism
Mean70%
TBR Mean70%/
Liver
TMR Mean70%/
Muscle
Intratumor Heterogeneity
(d) (mm3) (mm3) (mm3) (ID/cm3 wt) (ID/cm3 wt) (ID/cm3 wt)/liver (ID/cm3 wt)/muscle Range
(ID/cm3 wt)
IQR
(ID/cm3 wt)
IQR (%)
3A00 35 133.1 206.0 19.4 4.39 3.50 10.3 19.5 4.2 1.9 121%
3A01 35 111.6 160.2 30.9 1.84 1.49 4.7 4.0 1.5 0.5 42%
3B00 43 156.8 228.2 5.0 2.73 2.18 7.5 4.4 1.9 0.6 50%
3B01 43 185.7 247.1 12.8 1.93 1.51 3.6 3.6 1.3 0.5 58%
3C00 43 116.6 167.7 6.2 2.95 2.38 6.6 10.8 2.6 1.0 119%
3C01 43 113.1 222.7 23.4 1.82 1.42 5.1 5.5 1.4 0.5 52%
3C03 43 152.6 122.0 4.3 1.75 1.37 4.6 8.1 1.3 0.5 83%
4F01 49 158.1 81.3 6.8 3.68 2.97 8.5 7.2 3.2 1.7 179%
4F03 49 210.7 253.2 37.5 2.37 1.90 6.3 3.0 2.0 0.8 59%
4A00 84 93.8 100.8 2.3 1.59 1.29 4.2 5.0 1.4 0.4 65%
4C00 84 161.4 278.7 27.1 3.82 2.99 10.7 9.0 3.3 1.0 51%
4E03 84 168.8 148.2 11.0 2.16 1.73 6.7 3.3 1.4 0.7 72%
4F00 98 NA 227.5 27.8 3.96 3.05 8.5 12.7 3.2 1.2 59%
ean ±
standard
deviation
146.9 ± 34.2 188.0 ± 62.4 16.5 ± 11.8 2.7 ± 1.0 2.1 ± 0.8 6.7 ± 2.3 7.4 ± 4.7 2.2 ± 1.0 0.9 ± 0.5 78% ± 39%
edian 154.7 206.0 12.8 2.4 1.9 6.6 5.5 1.9 0.7 59%
5% CI of
median
[113.1, 168.8] [122.0, 247.1] [5.0, 27.8] [1.8, 3.8] [1.4, 3.0] [4.6, 8.5] [3.6, 10.8] [1.4, 3.2] [0.5, 1.2] [51%, 119%]
he [18F]-FDGmetabolism in tumorswasmeasured as themaximum (max) andmean (mean70%) [18F]-FDGuptake within the anatomic tumor volume. Across the cohort, [18F]-FDGuptake was normalized by
e injected activity and bodyweight of the individualmouse (ID/cm3*wt). Tumormetabolismwas compared to backgroundmetabolism in healthy liver, expressed as theTBR (ID/cm3*wt)/liver, and compared to
eletal muscle in a contralateral limb, expressed as the TMR (ID/cm3*wt)/muscle. The intratumor heterogeneity was calculated by comparing local maxima [18F]-FDG metabolism of subregions within each
mor and was expressed as the differences between highest and lowest of the subregions (range) and between the quartiles (IQR).
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Figure 2. [18F]-FDG biodistribution in mice with LAPC4-CR tumors.
Maximum intensity projection of the [18F]-FDG PET image acquired
at 60 minutes after injection of the radiotracer. The [18F]-FDG
uptake has been normalized by the injected activity and the mouse
body weight ([ID/cm3*wt]) and is shown using a false-color linear
scale for visual contrast. There is an expected biodistribution of
radiotracer with activity in normal tissue and physiologic radiotrac-
er excretion. Radiotracer uptake was also noted in the subcutane-
ous tumor.
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Figure 4. [18F]-FDG metabolism measurements in LAPC4-CR
xenograft tumors and in normal background tissues. Bar plots
indicate the mean uptake across the cohort of 13 mice. The
standard deviation between mice is indicated by the error bars.
*Significant P values (P b .01) in Wilcoxon signed-rank analysis.
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an inhaled anesthesia (2%-3% sevoflurane and air) for [18F]-FDG-PET/
CT studies.
Of note, the small size of the mouse muscles renders the analysis of
radiotracer uptake prone to partial volume averaging errors becauseFigure 3. [18F]-FDGmetabolism in LAPC4-CR xenograft tumors in 13mic
uptake within each subcutaneous tumor, as indicated by arrowheads. [1
radiotracer and displayed on a linear gray scale normalized by the injectesmall regions of fat, skin, or pelvic organs may be included within the
region of interest (ROI). Additionally, excreted [18F]-FDG and
metabolites in the urinary bladder introduce uncertainty due to
“spill-in” included in the ROI. The most uniform tissue ROI across
our cohort of mice was found to be the liver because the size of the
liver allowed consistent measurements with minimal partial volume
averaging effects.
A shared reference location defined the coordinates in image space
for the PET and CT; this allowed automatic and precise image
registration and PET/CT image fusion for image analysis. However,
in each mouse, the accuracy of image registration was verified bye. Figures show a coronal slice through the region of highest [18F]-FDG
8F]-FDG PET images were acquired at 60 minutes after injection of the
d activity and the mouse body weight ([ID/cm3*wt]).
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Figure 5. [18F]-FDGmetabolism in LAPC4-CR xenograft tumors compared to anatomic andmetabolic tumor volumemeasured on PET/CT.
Scatter plots show (a) [18F]-FDG metabolism versus anatomic tumor volume seen on CT and (b) [18F]-FDG metabolism versus metabolic
tumor volume seen on PET. The symbols represent the day postimplantation of tumors: 35 days (squares), 43 days (triangles), 49 days
(Xs), 84 days (crosses), and 98 days (circles). The best-fit linear correlations for the pooled data of the 13 xenograft tumors are also shown.
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that no motion during imaging or errors during reconstruction or
fusion had occurred. The fused PET/CT and CT images provided a
more accurate estimate of 3D tumor volumes than can be calculated
from physical palpation and caliper measurements. In addition, the
fused PET/CT images allowed better evaluation of regions of active
tumor metabolism. Fused PET/CT images showed regions within the
tumor mass where there was little or no [18F]-FDG uptake, often
located near the center of the subcutaneous mass, which was a
characteristic of soft tissue/tumor necrosis. Other metabolically
inactive regions coincided with small localized regions of calcified
tissue on the CT images. The presence of necrotic cores and
calcification of dead tissue in the LAPC4-CR cell line xenograft
tumors was found in earlier histopathology studies, which were done
on another cohort of mice during the development of the cell line.
Examples of stained tumor sections from that prior study, which
illustrates the typical pathology of LAPC4-CR xenografts, are shown
in Figure 6.Figure 6. Hematoxylin-stained tissue sections of LAPC4-CR xenogra
areas with a lack of staining indicate the acellular regions of necrosis
whereas (b) shows a tumor that had developed a necrotic core.Conclusion
This study reports the results of [18F]-FDG-PET/CT in a xenograft
model of the castration-resistant prostate tumor line LAPC4-CR. The
xenograft tumors showed [18F]-FDG uptake that was significantly
greater than uptake of skeletal muscle and liver. In addition, the
intensity of [18F]-FDG uptake was independent of anatomic tumor
size and metabolic tumor volume. Further work will investigate the
use of [18F]-FDG-PET/CT to quantify the response of LAPC4-CR
to novel agents and combination therapies using soft tissue and
possibly bone compartment xenograft models.
Acknowledgements
This work was supported by the Dana-Farber/Harvard Cancer
Center SPORE (Specialized Program of Research Excellence) in
Prostate Cancer, Developmental Project, NIH5P50 CA090381-10.
The authors also acknowledge the following individuals for their
contributions: Michaela Bowden, PhD, at Dana-Farber Cancer
Institute, coordinated laboratory experiments and facilitated access tofts with the nuclei of tumor cells stained deep purple. Amorphous
. Slide (a) shows small regions of necrosis within the tumor tissue,
Translational Oncology Vol. 8, No. 3, 2015 [18F]-FDG-PET/CT of LAPC4-CR CRPC Xenograft Model McCall et al. 153histological images on LAPC4-CR tumor models; Su-Chun Cheng,
PhD, Biostatistician at the Department of Biostatistics, Dana-Farber
Cancer Institute, provided expert advice on statistical analysis
methods; Amanda Christie, Research Technician at the CBIO/
LFIC, provided advice on small-animal handling and on tumor
growth patterns for Nu/Nu murine LAPC4-CR models, and
prepared tumor fragments for implantation; Ying Huang, MD,
PhD, Scientist at Dana-Farber Cancer Institute, performed
hematoxylin staining and analysis and provided representative
histological images of LAPC4-CR xenograft tumors; Li Jia, PhD,
Scientist at Dana-Farber Cancer Institute, provided expertise
in the LAPC4-CR cell line and prostate cancer tumor models;
Paul T. Kirschmeier, PhD of the Belfer Institute for Applied Cancer
Science, Dana-Farber Cancer Institute, and the CBIO/LFIC
provided scientific advice and facilitated access to experimental data
and images; Quang-De Nguyen, PhD, Director at the CBIO/LFIC,
provided expert scientific advice and facilitated access to experi-
mental data and images; Lei Qin, PhD, MRI Physicist at
Department of Imaging, Dana-Farber Cancer Institute, provided
imaging expertise in image acquisition and interpretation; Tanya
Tupper, Research Technician at the CBIO/LFIC, conducted the
preclinical data acquisition for this experiment, including small-
animal handling, and subcutaneous tumor implantation, tumor
growth monitoring, animal health monitoring, and in vivo PET/CT
imaging of the mice; Jeffery Yap, PhD, contributed to the
experiment design and defined the preclinical PET/CT imaging
protocols as the Senior Diagnostic Physicist at the Department
of Imaging, Dana-Farber Cancer Institute, and the CBIO/LFIC.
Dr Yap is currently Associate Director of the Center for Quantitative
Cancer Imaging at the Huntsman Cancer Center Institute,
University of Utah.
References
[1] Siegel R, NaishadhamD, and Jemal A (2013). Cancer statistics, 2013. CA Cancer
J Clin 63, 11–30.
[2] de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones
RJ, Goodman Jr OB, and Saad F, et al (2011). Abiraterone and increased survival
in metastatic prostate cancer. N Engl J Med 364, 1995–2005.
[3] ScherH, FizaziK, Saad S, TaplinM, SternbergCN,Miller K,DeWit R,Mulders P,
HirmandM, and Selby B, et al (2012.). MDV3100, an androgen receptor signaling
inhibitor (ARSI), improves overall survival in patients with prostate cancer post
docetaxel; results from the Phase 3 AFFIRM Study. GU ASCO; 2012.
[4] Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S,
Theodore C, James ND, and Turesson I, et al (2004). Docetaxel plus prednisone
or mitoxantrone plus prednisone for advanced prostate cancer.N Engl J Med 351,
1502–1512.
[5] de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G,
Bodrogi I, Mackenzie MJ, and Shen L, et al (2010). Prednisone plus cabazitaxel
or mitoxantrone for metastatic castration-resistant prostate cancer progressing
after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147–1154.
[6] Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern
CH, Ferrari AC, Dreicer R, and Sims RB, et al (2010). Sipuleucel-Timmunotherapy for castration-resistant prostate cancer. N Engl J Med 363,
411–422.
[7] Parker C, Heinrich D, O’Sullivan JM, Fosså S, Chodacki A, Demkow T, Cross
A, Bolstad B, Garcia-Vargas J, and Sartor O (2011). Overall survival benefit of
radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic
bone metastases in castration-resistant prostate cancer (CRPC): a phase III
randomised trial (ALSYMPCA). Proceedings of ECCO/ESMO Annual Meeting;
2011.
[8] Morris MJ, Akhurst T, Larson SM, Ditullio M, Chu E, Siedlecki K, Verbel D,
Heller G, Kelly WK, and Slovin S, et al (2005). Fluorodeoxyglucose positron
emission tomography as an outcome measure for castrate metastatic prostate
cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 11,
3210–3216.
[9] Meirelles GSP, Schöder H, Ravizzini GC, Gönen M, Fox JJ, Humm J, Morris
MJ, Scher HI, and Larson SM (2010). Prognostic value of baseline [18F]
fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan
in progressing metastatic prostate cancer. Clin Cancer Res 16, 6093–6099.
[10] Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Pinski JK, and Quinn
DI (2013). Baseline 18F-FDG PET/CT parameters as imaging biomarkers of
overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med 54,
1195–1201.
[11] Nahmias C and Wahl LM (2008). Reproducibility of standardized uptake value
measurements determined by 18F-FDG PET in malignant tumors. J Nucl Med
49, 1804–1808.
[12] Weber WA, Ziegler SI, Thodtmann R, Hanauske A-R, and Schwaiger M (1999).
Reproducibility of metabolic measurements in malignant tumors using FDG
PET. J Nucl Med 40, 1771–1777.
[13] Dandekar M, Tseng JR, and Gambhir SS (2007). Reproducibility of 18F-FDG
microPET studies in mouse tumor xenografts. J Nucl Med 48, 602–607.
[14] Whisenant JG, Peterson TE, Fluckiger JU, Tantawy MN, Ayers GD, and
Yankeelov TE (2013). Reproducibility of static and dynamic 18F-FDG,
18F-FLT, and 18F-FMISO microPET studies in a murine model of HER2+
breast cancer. Mol Imaging Biol 15, 87–96.
[15] Kukuk D, Reischl G, Raguin O, Wiehr S, Judenhofer MS, Calaminus C,
Honndorf VS, Quintanilla-Martinez L, Schönberger T, and Duchamp O, et al
(2011). Assessment of PET tracer uptake in hormone-independent and
hormone-dependent xenograft prostate cancer mouse models. J Nucl Med 52,
1654–1663.
[16] Emonds KM, Swinnen JV, Lerut E, Koole M, Mortelmans L, and Mottaghy FM
(2013). Evaluation of androgen-induced effects on the uptake of [18F]
FDG,[11C] choline and [11C] acetate in an androgen-sensitive and androgen-
independent prostate cancer xenograft model. EJNMMI Res 3, 31.
[17] Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, Phelps ME,
and Weber WA (2006). Impact of animal handling on the results of 18F-FDG
PET studies in mice. J Nucl Med 47, 999–1006.
[18] Brad JK, Carrie BH, Aaron RM, Mark WL, and Val JL (2009). NEMA NU
2-2007 performance measurements of the Siemens Inveon™ preclinical small
animal PET system. Phys Med Biol 54, 2359.
[19] Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, and
Joensuu H (1993). Influence of the blood glucose concentration on FDG uptake
in cancer—a PET study. J Nucl Med 34, 1–6.
[20] Tupper T, Yap JT, Franchetti Y, McDonagh E, Locascio TA, Kung A, and
Wang Y (2011). Utilizing ketogenic diet as an alternative to fasting in
preclinical 18F-FDG PET. World Molecular Imaging Congress (San Diego,
2011); 2011.
[21] Weber WA (2004). Brown adipose tissue and nuclear medicine imaging. J Nucl
Med 45, 1101–1103.
[22] Tatsumi M, Engles JM, Ishimori T, Nicely OB, Cohade C, and Wahl RL (2004).
Intense 18F-FDG uptake in brown fat can be reduced pharmacologically. J Nucl
Med 45, 1189–1193.
